Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study

CHIA-HSUIN CHANGYI-CHENG CHANGJOU-WEI LINChen, Shu-TingShu-TingChenLEE-MING CHUANGLai, Mei-ShuMei-ShuLai2022-12-302022-12-302015-030021-972Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/626867Metformin is the first-line oral therapy for type 2 diabetes with proven benefits against cardiovascular risk. Recent evidence suggested that acarbose might be similar to metformin in glucose-lowering efficacy and cardiovascular risk reduction. Therefore, international guidelines have suggested the use of acarbose as alternative first-line antidiabetic therapy.enACTIVATED PROTEIN-KINASE; IMPAIRED GLUCOSE-TOLERANCE; HEART-FAILURE; MYOCARDIAL-INFARCTION; BODY-COMPOSITION; DISEASE; MORTALITY; SULFONYLUREAS; OUTCOMES; THERAPY[SDGs]SDG3Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort studyjournal article10.1210/jc.2014-2443255550402-s2.0-84924934011WOS:000353358900063https://api.elsevier.com/content/abstract/scopus_id/84924934011